These phenotypes were further supported with additional immune markers including PD-1, PD-L1, granzyme B, FoxP3, CD20, CD4, CD3, CD45RO, TCF1, CD103, and CD95 to investigate the complexity of immunity in the tumor microenvironment of the lung cancer patients’ tissues. This evidence concerns the gene CD4 and neoplasm.